Year archive

Vivesto — 2015 filings

All 56 regulatory filings released by Vivesto (VIVE) in 2015, sourced directly from the official regulator.

56 Filings

2015 Period

2015 filings (56)

Filing	Released	Lang
Oasmias nästa generations läkemedelskandidat Docecal godkänd för kliniska prövningar Regulatory Filings	2015-12-07	Swedish
Oasmia Pharmaceutical’s Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials Regulatory Filings	2015-12-07	English
Interim / Quarterly Report 2015 Interim / Quarterly Report H1 2015	2015-12-03	Swedish
Interim / Quarterly Report 2016 Interim / Quarterly Report H1 2016	2015-12-03	English
Major Shareholding Notification 2015 Major Shareholding Notification	2015-12-01	English
Publication of change in the total number of shares and votes in Oasmia Declaration of Voting Results & Voting Rights Announcements	2015-11-30	English
Offentliggörande av förändring i det totala antalet aktier och röster i Oasmia Share Issue/Capital Change	2015-11-30	Swedish
Oasmia Pharmaceutical’s Lead Human Cancer Drug Paclical® Generates Strong Interest at the 19th Annual Russian Cancer Congress Regulatory Filings	2015-11-20	English
Starkt intresse för Oasmias cancerläkemedel Paclical® vid den 19:e årliga ryska cancerkongressen Regulatory Filings	2015-11-20	Swedish
Oasmia bekräftar finala positiva resultat för Paclical® från en jämförande studie med Abraxane® Legal Proceedings Report	2015-11-05	Swedish
Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane® Earnings Release FY 2015	2015-11-05	English
Oasmia erhåller ny order för den Ryska marknaden till ett värde av 7,5 miljoner dollar till slutkund Earnings Release FY 2015	2015-10-30	Swedish
Oasmia Pharmaceutical receives order of $7.5 million in end-user value for the Russian market Earnings Release FY 2015	2015-10-30	English
Oasmia Pharmaceutical AB meddelar att den amerikanska NASDAQ-noteringen och emissionen är slutförd Share Issue/Capital Change	2015-10-29	Swedish
Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing Share Issue/Capital Change	2015-10-29	English
Oasmia har erhållit den första ordern på Paclical till den Ryska marknaden Earnings Release Q4 2015	2015-10-28	Swedish
Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical in Russia Earnings Release Q4 2015	2015-10-28	English
Nexttobe extends loan to Oasmia Capital/Financing Update	2015-10-23	English
Nexttobe förlänger lån till Oasmia Capital/Financing Update	2015-10-23	Swedish
Oasmia uppdaterar registreringsdokument inför den amerikanska börsintroduktionen Capital/Financing Update	2015-10-20	Swedish
Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering Capital/Financing Update	2015-10-20	English
Paclical lanseras kommersiellt i Ryssland och OSS Legal Proceedings Report	2015-10-05	Swedish
Oasmia Pharmaceutical AB Announces Commercial Launch of Paclical in Russia and CIS Countries Regulatory Filings	2015-10-05	English
Communiqué from Oasmia’s Annual General Meeting 2015 AGM Information	2015-09-30	English
Kommuniké från årsstämma 2015 AGM Information	2015-09-30	Swedish
Oasmia Pharmaceutical har uppdaterat sin registreringsansökan om introduktion på NASDAQ USA genom tillägg av teckningsoptioner vilket potentiellt ökar storleken på emissionen Capital/Financing Update	2015-09-28	Swedish
Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Adds Warrants That Potentially Increase Gross Size of Offering Capital/Financing Update	2015-09-28	English
Interim / Quarterly Report 2015 Interim / Quarterly Report Q2 2015	2015-09-03	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-09-03	English
Notice convening the Annual General Meeting of Oasmia Pharmaceutical AB AGM Information	2015-08-31	English
Kallelse till årsstämma för Oasmia Pharmaceutical AB AGM Information	2015-08-31	Swedish
Annual Report 2015 Annual Report FY 2015	2015-08-21	Swedish
Annual Report 2015 Annual Report FY 2015	2015-08-21	English
Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Announces Investor Roadshow Capital/Financing Update	2015-08-17	English
Oasmia Pharmaceutical AB har uppdaterat sin registreringsansökan om introduktion på NASDAQ USA och inleder roadshow för amerikanska investerare Capital/Financing Update	2015-08-17	Swedish
Oasmia Pharmaceutical Announces Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane® Earnings Release FY 2015	2015-08-04	English
Oasmia redovisar positiva resultat för Paclical® i en jämförande studie med Abraxane® Regulatory Filings	2015-08-04	Swedish
Oasmia Pharmaceutical Extends Form F-1/A Registration Statement to Include New Key Material Data and Final Full-Year Financials Report Publication Announcement	2015-08-03	English
Oasmia uppdaterar prospektet inför den amerikanska noteringen med ny väsentlig information Capital/Financing Update	2015-08-03	Swedish
Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow Capital/Financing Update	2015-07-07	English
Oasmia Pharmaceutical ansöker om börsnotering på NASDAQ i USA, samt genomför roadshow för amerikanska investerare Capital/Financing Update	2015-07-07	Swedish
Audit Report / Information 2015 Audit Report / Information FY 2015	2015-06-04	Swedish
Annual Report 2015 Annual Report Q4 2015	2015-06-04	English
Oasmia genomför ändringar i styrelse och ledning Board/Management Information	2015-05-29	Swedish
Changes in Oasmia’s Board of Directors and Management Board/Management Information	2015-05-29	English
Oasmia kallar till extra bolagsstämma Board/Management Information	2015-05-07	Swedish
Oasmia gives notice of Extraordinary General Meeting Board/Management Information	2015-05-07	English
Resultat från Oasmias fas III-studie presenteras vid ASCO Earnings Release FY 2015	2015-04-24	Swedish
Results from Oasmia’s Phase III study will be presented at ASCO Regulatory Filings	2015-04-24	English
Paclical® har fått marknadsgodkännande i Ryssland Regulatory Filings	2015-04-20	Swedish
Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation Regulatory Filings	2015-04-20	English
Oasmia's lead cancer product Paclical(r) receives market approval in the Russian Federation Regulatory Filings	2015-04-20	English
Interim / Quarterly Report 2015 Interim / Quarterly Report 9M 2015	2015-03-05	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report 9M 2015	2015-03-05	English
Oasmia inleder klinisk fas II-studie med Doxophos Vet för behandling av lymfom i hund Regulatory Filings	2015-02-17	Swedish
Oasmia initiates clinical Phase II study with Doxophos Vet for the treatment of canine lymphoma Regulatory Filings	2015-02-17	English

Filings by year

2026 16 filings
2025 23 filings
2024 13 filings
2023 27 filings
2022 59 filings
2021 29 filings
2020 53 filings
2019 224 filings
2018 96 filings
2017 81 filings
2016 76 filings
2015 56 filings
2014 70 filings
2013 38 filings
2012 42 filings
2011 48 filings
2010 41 filings
2009 44 filings
2008 22 filings
2007 10 filings